Abstract:Objective To explore the therapeutic effects of sirolimus on nephritic mice with chronic rejection,and the possible mechanisms. Methods B6D2F1mice transplanted with cell mixture of spleen,thymus,and lymph nodes from DBA /2 spleen,thymus,and lymph nodes cell mixture were used to construct murine model with chronic rejection,and the transplanted mice were randomly divided into two groups. Mice in the sirolimus-treated group were given sirolimus orally in a dose of 1 mg /( kg·d) for 12 consecutive weeks,while mice in the control group were administered with equal amounts of olive oil. Nephritis in mice was confirmed by urine protein determination and histopathological analysis. Enzyme immunoassay was used to detect the serum levels of anti-DNA antibodies including anti-ds DNA IgG,anti-ds DNA IgG1,anti-ds DNA IgG2a,anti-ss DNA IgG,anti-ss DNA IgG1,and anti-ss DNA IgG 2a. Real-time PCR analysis was conducted to evaluate the gene expression of interleukin-6( IL-6),tumor necrosis factor-α( TNF-α),interferon-γ( IFN-γ),interleukin-1β( IL-1β),monocyte chemoattractant protein 1( MCP-1),regulated upon activation normal T cell expressed and secreted( RANTES),B lymphocyte chemoattractant( BLC),transforming growth factor β1( TGF-β1),and collgen I. The proportion and activation of T and B lymphocytes in peripheral blood or spleen were determined by flow cytometric analysis.Results At the end of observation period,the incidence of nephritis in mice treated with sirolimus was significantly lower than that of mice treated with olive oil( P 0. 05). Histopathological evaluation of kidney specimen showed evident vascular intimal hyperplasia and mononuclear cell infiltration in control group. In contrast,no obvious kidney lesions was observed in sirolimus-treated mice. Furthermore,the levels of anti-DNA antibodies and the transcriptional expression of lupus IL-6,TNF-α,IFN-γ,IL-1β,MCP-1,RANTES,BLC,TGF-β1,and collgen I were significantly down-regulated in sirolimus-treated group as compared with control group. Flow cytometric analysis indicated that both of the proportion of activated /memory T cells in peripheral blood and the expression level of surface activation markers on T and B lymphocytes in spleen were significantly decreased in mice exposed to sirolimus as compared with those exposed to olive oil( P 0. 05). On the other hand,the proportion of CD4+FOXP3+regulatory T cells in spleen was significantly upregulated in sirolimus-treated group as compared with control group. Conclusion Sirolimus may inhibit the proliferation and activation of effector cells and downregulate the expression of chemokines and inflammatory factors through up-regulation of CD4+FOXP3+T cells,thus effectively ameliorating the progression of nephritis in mice.

Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis.

Therapeutic Effects and Possible Mechanisms of Sirolimus on Nephritic Mice with Chronic Rejection

Influence of Sirolimus-Induced TGF-β Secretion on Mouse Treg Cell Proliferation.

Intestinal Dysbiosis Correlates With Sirolimus-Induced Metabolic Disorders In Mice

Mtor Inhibition Attenuates Dextran Sulfate Sodium-Induced Colitis by Suppressing T Cell Proliferation and Balancing TH1/TH17/Treg Profile

Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions1

Oral Treatment with SEW2871, a Sphingosine-1-phosphate Type 1 Receptor Agonist, Ameliorates Experimental Colitis in Interleukin-10 Gene Deficient Mice.

Sirolimus therapy for a cGVHD murine model with scleroderma by up-regulating Tregs

Study of immunoregulatory effect of sirolimus on xenotransplantaion with arterial patch

The advantage of Sirolimus in amplifying regulatory B cells and regulatory T cells in liver transplant patients

Anti-mouse CD52 Treatment Ameliorates Colitis Through Suppressing Th1/17 Mediated Inflammation and Promoting Tregs Differentiation in IL-10 Deficient Mice

Selective Sequestration of STAT1 in the Cytoplasm Via Phosphorylated SHP-2 Ameliorates Murine Experimental Colitis

Laquinimod Ameliorates Spontaneous Colitis in Interleukin-10-gene-deficient Mice with Improved Barrier Function

Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn'S Disease Mouse Model

Sirolimus Inhibits Endogenous Cholesterol Synthesis Induced by Inflammatory Stress in Human Vascular Smooth Muscle Cells

HG-9-91-01 Attenuates Murine Experimental Colitis by Promoting Interleukin-10 Production in Colonic Macrophages Through the SIK/CRTC3 Pathway.

Immunological tolerance induced by Sirolimus combine with modified sTNFRI-IgGFc gene in rat dendritic cells

Interleukin-10 Gene-Carrying Bifidobacteria Ameliorate Murine Ulcerative Colitis by Regulating Regulatory T Cell/t Helper 17 Cell Pathway

Anti-atherosclerotic Effects of Sirolimus on Human Vascular Smooth Muscle Cells

Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance

HSF1 promotes CD69+ Treg differentiation to inhibit colitis progression